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To achieve viral suppression in children on antiretroviral treatment (ART) optimal adherence is 
essential. Generally in clinical practice > 95% of the prescribed ART doses should be taken for 
patients to have an undetectable viral load < 400 copies/ml. Maintaining adherence > 95% in 
children on ART is not only challenging but difficult to measure. Barriers to optimal adherence 
may be related to caregiver’s factors and child/caregiver forgetfulness, taste of medicine, 
financial constraints in accessing care and side-effects. Prior research indicates that the validity 
of adherence information is improved when multiple sources of information are used. However, 
little information is available on interventions to improve assessment of adherence in HIV 
infected children on ART. 
Objective 
The aim of this study was to assess adherence to ART in a rural paediatric cohort, to determine 
if monthly adherence assessment by pill count is a reliable predictor of virological outcomes 
and to identify reasons for non-adherence as reported by the children or caregiver themselves at 
each visit. 
Methodology 
A retrospective cohort study was conducted using routinely collected data from children 
enrolled into the CAPRISA 052 AIDS Treatment Program from June 2008 – September 2013 in 
a rural area of KwaZulu-Natal, South Africa.  
Results 
A total of 79 children, with a median age of 7.1 years, enrolled into the CAPRISA 052 AIDS 
Treatment program. Of these, 78 children were initiated on antiretroviral treatment. Monthly 
adherence by pill count was categorized into high ≥95% and low <95%.  Overall median 
monthly adherence to treatment was 87.8% (interquartile range (IQR): 71.0-99.6%) at month 
six, 88.9% (IQR: 77.1-99.8%) at month 12 and 90.8% (IQR: 79.1-99.2%) at month 24. The 
proportion of children with an undetectable viral load (< 400 copies/ml) were 84.0% (n=63) at 
month six, 86.6% (n=58) at month 12, and 84.5% (n=49) at month 24. Multivariate analysis 
demonstrated that children with an overall adherence by pill count > 95%, children with a 
baseline WHO stage 3 or 4, if the primary caregiver was a family member instead of the 
biological parents and if the primary caregiver was the recipient of any financial grant were 




In conclusion, this treatment program demonstrated sustained high adherence to treatment over 
a two year period, with monthly pill count being a good tool to measure adherence and viral 
load assessment remaining the gold standard for assessing treatment success. 
xii 
 
STRUCTURE OF THE DISSERTATION 
 
This dissertation was written in accordance with the Guidelines for Presentation of Masters 
Dissertations provided by the College of Health Sciences, University of Kwa-Zulu-Natal, 2015. 
There is a single reference list in the Vancouver format for references cited in chapters 1 and 4.  
The dissertation comprises of the following chapters: 
Chapter 1: Introduction highlights the overall research problem and reason for this study with a 
thorough literature review that was conducted, including table 1 which is a thorough review of 
the literature summarising the results of 39 studies of adherence to ART in children and 
provides data on possible predictors for non-adherence and reasons for non-adherence. The aim, 
hypotheses and objectives addressed in the manuscript are also listed here. This chapter ends 
with a conceptual framework around adherence for HIV infected children on ART.  
Chapter 2: Methods, comprehensively outlines the processes/procedures conducted throughout 
the CAPRISA 052 AIDS Treatment Program, including the role of the pharmacist, data 
collection and data management. This section also describes the methodology for the secondary 
analysis and describes the study setting.  
Chapter 3 includes the Manuscript titled ‘Assessing adherence to antiretroviral therapy in a 
rural paediatric cohort in KwaZulu-Natal, South Africa’ submitted for publication to the 
journal AIDS & Behavior. It is presented in the required format for that journal and is the final 
revised submitted version as approved by all co-authors. All objectives and aims of the study 
were addressed in this manuscript. It also included a detailed outline of my contribution towards 
the manuscript and the CAP 052 AIDS Treatment Program. Correspondence from the journal 
after submission can be found in Appendix C.  
Chapter 4 discusses the overall conclusion of the study as well as recommendations for clinical 






















CHAPTER 1: INTRODUCTION 
 
1.1 Background and the context for the study  
 
Since the discovery of Human Immunodeficiency Virus (HIV) in the early 1980’s, millions of people 
have either died from this disease or been affected by associated comorbidities. According to the 
World Health Organisation (WHO) in 2014, 2.6 million children (<15 years) were living with HIV 
globally, 220 000 children were newly infected with HIV and 150 000 children demised due to 
Acquired Immune Deficiency Syndrome (AIDS)-related illnesses (1). Sub-Saharan Africa remains the 
region with the highest number of children living with HIV, with 2.3 million children living with HIV 
in 2014, and only 30% of these children (age 0 – 14 years) accessing antiretroviral treatment (ART) 
(2). In South Africa, 360000 children were reported living with HIV in 2013 (3) with only 156700 
initiated on ART (4). 
ART, which consist of a combination of at least three different antiretroviral drugs (ARVs) taken 
daily in the treatment of HIV infection. ARVs have not only improved the quality of life of children 
on treatment but have also decreased the mortality and morbidity rates in HIV infected children. 
However, for these ARVs to achieve its aim in rapidly decreasing viral load, increasing CD4 cell 
count and to delay disease progression, adherence to ART is vital (5). Achieving optimal adherence to 
ARVs (>95% of doses per month ingested) in children is challenging and there is little information or 
guidance on how to improve, measure or determine adherence. A prospective observational study, 
which explored the agreement between pill count and viral load in adult patients on ART, found that a 
95% cut-off for adherence by pill count had a closer relationship with viral load outcomes than a 90% 
cut-off (6). A secondary analysis conducted in a South-African paediatric cohort (children < 2years of 
age) concluded that adherence by medication return of < 85% increased the likelihood of poor viral 
suppression (7).  Therefore it is unclear whether the > 95% cut off is appropriate for paediatric 
patients. 
Different adherence monitoring methods used by other studies in South Africa included self-report by 
caregivers, medication return assessments, medication event monitoring systems, visual analog scale, 
and pharmacy refill (8-10). Amongst these methods, medication return has been shown to have a 
positive correlation with virologic response in children (7, 8). 
Factors previously identified that may negatively influence the ability for a child to adhere to lifelong 
ART can be related to numerous issues such as caregiver, children, healthcare staff and medication 
(11-13). Health care staff are responsible to ensure quality of patient-care provider relationships and 
ensure access of care (14). Sustainability of drug supply, relationship between the healthcare provider 
and the caregiver, and the possibility that the same healthcare provider might not examine you at each 
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visit are amongst the barriers that healthcare providers face in supporting medication adherence (11). 
Other barriers identified by healthcare staff are: clinic infrastructure, waiting times, overcrowding and 
language barriers(15). All of these structural barriers have an impact on the privacy of the patient. 
Some challenges or barriers to adherence reported by caregivers, patients and clinical staff in previous 
literature are: social circumstances, disclosure to the child, psychosocial issues, treatment regimen 
complexities and primary caregiver support (5, 9, 16, 17). Early detection and resolution of these 
barriers will improve the clinical outcomes of the children on ART. These factors can all potentially 
negatively impact adherence to ARVs, therefore, reasons for children failing to adhere to their ARV 
regimens should be monitored, investigated and successful and sustainable interventions are needed 
(18).  
Prior research indicates that the validity and reliability of adherence information is improved when 
triangulation or multiple sources of adherence measures are used (13, 14, 19). Few studies published 
clinical outcomes such as viral load suppression and other objectives methods to assess adherence in 
children. With safety blood monitoring only being done at enrolment, month six and then annually in 
accordance with the South African National Department of Health Antiretroviral Treatment 
Guidelines (20), detecting adherence challenges, treatment failure or virologic failure might delay 
health care staff to intervene and assist with these challenges. The monthly pill count could be 
designed to collect valuable information which could be incorporated into clinical care as a 
monitoring tool. If pill count is found to be a reliable predictor of viral load outcomes, non-adherence 
can be monitored by clinical staff and this early intervention may perhaps limit treatment and 
virological failures in paediatric patients on ART. This early discovery of potential treatment failure 
due to poor adherence to medication is essential to maintain good clinical outcomes. Adherence 
support services should be offered if non-adherence persists to minimize the possibility of having to 
switch to second line treatment. 
This proposed study aimed to assess adherence outcomes for children on ART in a rural setting and 
determining whether the monthly pill count can be defined as a reliable measure of medication 
adherence, or as an independent predictor of virological failure where poor rural settings do not have 
easy access to frequent viral load monitoring.  
 
1.2 Literature Review 
 
Table 1 is a thorough review of the literature summarising the results of 39 studies of adherence to 





1.2.1 Antiretroviral Treatment and Viral load  
 
In South Africa, HIV infected children ART regimens for first line include two nucleoside reverse 
transcriptase inhibitors (NRTIs), abacavir and lamivudine, and one protease inhibitors (PIs), lopinavir 
/ ritonavir for those children less than 10kg. All other children are treated with two NRTIs, abacavir 
and lamivudine, and one non-nucleoside reverse transcriptase inhibitors (NNRTIs), efavirenz (20). 
Second and third line treatment depends largely on the first line treatment received at initiation and 
clinician and / or specialist decision.  
ART aims to rapidly decrease the viral load of a patient, and assist in maintaining an undetectable 
viral load and increase the CD4 cell count (21) which will then decrease mortality and morbidity 
rates, prolong and improve the quality of life for these children. 
Good adherence has, in previous studies, been identified or recognized as a positive predictor of viral 
load suppression in children receiving Highly Active Antiretroviral Treatment (HAART) (5, 19, 22-
27). Although achieving complete viral suppression in HIV infected children initiated on HAART is 
possible, maintaining this is still reported as a major challenge (19).  
Some possible predictors for virologic failure that have been identified in some studies are non-
adherence (5, 23), baseline WHO stage 3 and 4 (28), not having the biological parent as the primary 
caregiver (18), travelling distance and time to the clinic (18, 23), poor MEMS adherence (29), 
younger age (23), children on ART for less than one year (30) and low household income (31).  
 
1.2.2 Adherence Measures 
 
The lack of a defined standard measure of medication adherence remains a limitation for all adults, 
adolescents and children on ART (25, 32, 33). The main aim with measuring adherence in children on 
ART is to be able to discover virologic and / or treatment failure as soon as possible and to be able to 
address this immediately to improve the clinical outcomes of these children (34). 
To maximize the of adherence data collected and to minimize the over estimation of adherence often 
caused by self-report bias, suggestions have been made by previous studies to collect adherence data 
from multiple sources (10, 13, 19, 35, 36). In rural communities, the feasibility and availability of 
having multiple sources to collect adherence data is challenging and therefore the available sources 
have to be reliable to ensure that adherence is measured correctly and that good clinical outcomes are 
being met.  
Currently methods being used by different facilities to measure and monitor medication adherence can 




Figure 1: Different methods used for measuring medication adherence 
Indirect methods to measure adherence are inexpensive, easily and readily available but they have 
their own limitations. Pharmacy adherence measures currently being used in practice include pill 
count, self-report and pharmacy refill data. These measures have been shown to be very reliable 
predictors of virological outcomes in a resource poor setting (37). Children are often on liquid ART 
formulations due to difficulty in swallowing tablets, and it is challenging in measuring syrups when 
dispensed, administered and returned. Self-reported measures including questionnaires and interviews 
have been considered to be the most practical measure of adherence (14), but detecting poor 
adherence using self-report is challenging (38). The major limitations contributed by these self-
reported measures are recall and social desirability biases. A patient’s memory may fail and therefore 
adherence might be overestimated (39). Liquid formulations are difficult to administer and influence 
the accuracy of pharmacy refill data (10) as syrups may be spilled during administration, containers 
may break and there is difficulty measuring correct quantities with syringes.  
Medication Event Monitoring System (MEMS), real-time measurement of adherence, has been 
proven to be useful for calculating adherence but may give underestimated or overestimated 
adherence results (10), but still remains one of the best methods to measure adherence (33, 40). 
Direct methods to assess medication adherence are an objective measure which provides evidence that 
the patient has actually been taking the drug. The different direct methods available are to detect a 
drug / metabolite in urine or blood samples, detection of biological markers provided by a specific 
drug and directly observing whether the patient is taking the drug. These methods are challenging 
when adherence is assessed quantitatively. Accuracy of these methods are influenced by the half-life 
of the drug, the metabolism and volume of distribution for each individual patient that may differ 
(41). These direct methods are also often too expensive, time-consuming and may underestimate 




























Non-adherence has been associated with the increase of viral load and decrease of CD4 count (19, 
22). It has been highlighted that viral resistance and treatment failure can be attributable to a patient 
that does not adhere to their prescribed antiretroviral medication regimen dose, time interval and 
frequency (13). 
ART requires commitment from both the primary caregiver and the child. Children may not always 
understand the reason for being on lifelong ART or what their medication regimen is for (35), so they 
do not understand the impact that non-adherence may have on the clinical outcomes and quality of 
life. Some of these children have lost one or both of their biological parents and are then often left in 
the care of other family members (29). They often then have to rely on their primary caregiver to 
administer the medication and to take the responsibility of maintaining good adherence to ART 
medication (10).  
As important as it is for the caregiver to take control of the administration of the medication, they 
themselves might also be ill, elderly or may find it difficult to always be able to keep up with this 
burdensome responsibility. Elderly caregivers might struggle with administering medication in the 
form of syrups, dosages may change monthly as the paediatric patient gains weight (Appendix D-I), 
caregivers may forget what time or what quantity of the prescribed medication should have been 
given to the paediatric and financially it may not always be possible for them to adhere to the clinic 
appointment dates, especially if they have to travel far to get to their local clinic or hospital (22).  
All of these obstacles emphasize the importance of intervening in this primary caregiver support. We 
need to understand which barriers for adherence exist for both the primary caregiver of the paediatric 
and the paediatric, and then aim to find a sustainable solution to this problem. This intervention 
should be considered to be an ongoing process as the primary caregiver might change over time. 
 
1.2.4 Reasons for non-adherence 
 
Some reasons identified for missing doses in previous studies were reported as: difficult treatment 
regimens (13), caregiver factors and support (13, 43), psychological issues (44), medication side 
effects (24), non-disclosure to the child on ARV’s (32), pill burden or difficult regimens (24, 45), 
biological parents not the primary caregiver, communication between primary caregiver and 
paediatric patient, and the health of the caregiver (36). 
Paediatric patients may not always remember, (24, 46) if unsupervised, to take their own medication. 
They may reject taking medication and also miss doses when vomiting (46). 
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Most reasons for missing doses are normally collected by self-report (13, 19, 22, 24) and may often 
lead to recall bias. The paediatric patient or the primary caregiver might not always be willing to 
admit the truth when they forget to give the medication or cannot always remember if they have 
missed giving medication dosages to the paediatric patient, they will then give any answer to ‘please’ 
the clinical staff. This social desirability bias makes it difficult to understand the context of the 
problem and formulate a suitable intervention for the reasons for missing doses.  
 
1.2.5 Adherence estimates by pill count / medication return 
 
Clinic pill counts for Zambian children indicated overall median adherence of 96.9%. This cohort had 
no children with an adherence < 80%. For unannounced home-visit pill count the median adherence 
was 93.4%, but for this measure 62% children had adherence < 95% and 10% had an adherence < 
80% (47). Similarly for children in Uganda adherence estimates for unannounced pill counts / liquid 
formulations was high with a median adherence of 97.3% (48). Similarly in DarEs Salaam, Tanzania 
adherence >95% measured by medication return for all children was 97% (30). In Ethiopia, children 
part of a cross-sectional study showed poor adherence >95% (34.8%) by using unannounced home-
based pill counts (28). 
In South Africa, 79% of children in Cape Town achieved annual medication return adherence >90% 
and 73% of these children presented with an adherence >95% (8). A longitudinal study in Nyanga, 
Cape Town, 67% children had an adherence of 100% with returned syrups, this is overestimated when 
compared to MEMS in this study (10).  
 
1.2.6 Association between viralogic response and adherence by pill count  
 
Few studies have published data on the association between adherence by pill count and virologic 
response in children. Children in a cross-sectional study in Cape Town, South Africa, suggested that 
medication return strongly predicted viral response (8). In Zambia at the Macha Hospital, a 
prospective observational study demonstrated that children with a lower risk of achieving viral 
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status 
3. Pill burden 
4. ART regimen 
containing NNRTIs 
5. Living in 
individual housing 
Medication out of stock (43%) 
Forgetfulness (22%) 
Vomiting (14%) 




















6. Caregiver other 







18months – 18 
years 









and viral load) 
Mean viral load: 
 
50 cells/ml/103 for 
those in residential 
care 
 
81.3 cells/ml/103 for 
those in family care 
Global adherence 
85.7% 
Not available / not 
done 
1. Caregiver hours 
worked 
2. Nausea as side-
effect of ARVs 
3. Age of child 
Primarily caregiver related 
Caregiver forgetting (35%) 
Caregiver schedule changed 
(35%) 
Medication finished (30%) 











Not available / not 
done  
Viral Load after 6-
12months on 
Antiretroviral therapy 




Load defined as 
having a viral load < 
25 copies/ml 
Not available / not 
done  
Not available / not 
done  
Not available / not 
done  




































Not available / not 
done 
Not available / not 
done 
Not available / not 
done 
Not available / not 
done 
Pharmacy out of stock 
Financial constraints to 
purchase medication  
No reason for no drugs at home  
Mother daily schedule change 
Child away from home  
Child admitted to hospital  
Child vomited  





n= 12 caregivers 












Not available / not 
done  
Not available / not 
done  
Not available / not 
done  
Not available / not 
done  
Pill-burden 
Fear of stigma and 
discrimination 
Transportation challenges due 
to cost and access 
ARVs knowledge lacking 










Not available / not 
done  
4% : 95-100% 
adherence 
Not available / not 
done  
Not available / not 
done  
Daily routine 
No help to remember 
Spillage of medicine 
Forgot 
Away from home 
Don’t feel like taking it 








































Load defined as 
having a viral load < 
400 copies/ml) 
1. 82.6% Full 
Adherence 
2. 60.9% Full 
Adherence 
3. 76.1% Full 
Adherence 
4. Concordance of 
three measures = 
47.8% Full Adherence 
 




Not available not 
done  












Not available / not 
done 
70% of the children 
experienced a viral 








Load defined as 
having a viral load < 
400 copies/ml 
Not available / not 
done  
1. WHO stage 3 
and 4 
Not available / not 
done  





n= 25 nurses 
n= 8 guardians, 




report by nurses 
and guardians  
Not available / not 
done  
Not available / not 
done  
Not available / not 
done  
Not available / not 
done  
Lack of food 
Limited disposable income 
Unable to take child to hospital 
Poor memory 
Forget review dates 
Children remind the guardians 









































4. Pharmacy refill 
5. Measurement 
of returned syrups 






Load defined as 
having a viral load < 
50 copies/ml) 
 
1. 92% Overall 
adherence /16% >95% 
 
 
2. 100% Overall 
Adherence/45% >95% 
3. 100% Overall 
Adherence/43% >95% 
4. 100% Overall 
Adherence/49%>95% 






Not available / not 
done  








months – 13 years 
n= 101 
(18) 









Load defined as 
having a viral load < 





Load defined as 
having a viral load < 










2. Long distances 
to travel to the 
clinic, more than 
20km 
3. Poor adherence 
on at least one 
occasion 
Not available / not 
done  



































Not available / not 
done 
Not available / not 
done 
Not available / not 
done 
1. Being fed-up with 
medication regimen 
2. Forgetting by both 
caregiver and 
children 
3. Difficulty with 




No assistance in the home 
Child does not want to take the 
medication  
Clinic appointments repeatedly 
missed 
Mistrust in medication 
High level of curiosity 









1. Pill counts 
2. Caregiver 
report 

















Load defined as 
having a viral load < 
50 copies/ml) 
1. 96.9% median 
adherence 
2. 94.8% median 
adherence 
3. 97.4% median 
adherence 
4. 94.8% median 
adherence 






1. Age and Sex 
2. Monthly 
Household income 
3. CD4 % 
















Month 6 – 88.5% 
Undetectable Viral 
Load 
Month 12 – 88.3% 
Undetectable Viral 
Load 









2. Longer travel 
times 









antiretroviral drugs  












































Load defined as 
having a  viral load < 
400 copies/ml) 
49% children Non-
Adherent (adherence < 
90%) 
Not available / not 
done  
Not available / not 
done  
By caregiver: 
Regimen issues (13%) 
Child-related issues (25%) 
Daily routine changed (18%) 
Child not at home (17%) 
Child did not want to take the 
medication (12%) 
Child feeling well (11%) 
Busy (11%) 
By child: 
Regimen issues (29%) 
Child related issues (33%) 
Child slept at dose time (28%) 
Child not at home (23%) 
Busy (22%) 










1. 3-day recall 
2. 30-day Visual 
Analog Scale 
3. Unannounced 





ART at baseline with 
detectable viral load: 
Month 6 – 36.7% 
Month 12 – 38.2% 
ART initiated at 
baseline with 
detectable viral load: 
Month 6 – 38.5% 
Month 12 – 25.0% 
 
(Undetectable Viral 
Load defined as 
 
1. 100% median 
adherence 
2. 97.4% median 
adherence 
3. 97.3% median 
adherence 










1. Hospitalization of 
child in past three 
months 
2. Use of liquid 
formulations 
3. Caregivers use of 
alcohol 


























Children < 15 
years  









Not available / not 
done  
93.3% >95% adherence 
for past seven days 
 
34.8% >95% adherence 
Not available / not 
done  
1. Marital status of 
caregiver 
2. Known HIV status 




Child refusal (27.3%) 
Lack of food to take with 
Drug run out at home 
Child slept 
Transportation problem 








months – 17 years 





child / adolescent 
 
 
Not available / not 
done  
59.2% Full Adherence 
 
76.1% >95% adherence 
 
Not available / not 
done  
1. Mother as primary 
caregiver 
2. Age, children less 
than 5 years more 
likely to be non-
adherent 
3. Presence of co-
morbidity  
Forgetfulness by caregiver 
(55.2%) 
Caregiver travelled (25.3%) 
Caregiver ill (11.5%) 
Drugs finished (18.4%) 
Child refused drugs (11.5%) 
Child slept (9.2%) 
Child vomited (9.2%) 
Drugs are too many (6.9%) 
Child went to school (6.9%) 
Drugs are bitter (3.4%) 
No money for transport (2.3%) 













Not available / not 
done  
24hour recall 
questionnaire – 84.2% 
Adherence 
 
7 day recall 
questionnaire –  
72.2% Adherence 











































5. Lack of virological 
control 
6. Lack of religious 
practice by caregiver 






















Not available / not 
done  
98% adherence >95% 
 
97% adherence >95% 





2. Age of patient 
3. Patients on 
antiretroviral 





Not available / not 
done  












Not available / not 
done  
89.1% in last 3 days 
adherence >95% 
 
83.4% in last 7 days 
adherence >95% 
 
Not available / not 
done  
1. Sex ,Males more 
adherent 
2. Age 
3. Marital status of 
caregiver 
4. Religion of 
caregiver 
4. Age of caregiver 
Caregiver forgot (2.2%) 
Side-effects (16.3%) 
Drug ran out at home (2.2%) 
Chid not at home (5.9%) 
Lack of privacy (8.1%) 
Child illness (8.9%) 
Difficulty in swallowing pills 
(13.3%) 
Pill-burden (15.5%) 

































3 day assessment 
 
7 day assessment 
Not available / not 
done 
90.4% adherence >95% 
 
 
98.7% adherence > 
95% 
 
96.8% adherence > 
95% 
Not available / not 
done 
1. Age of the child 
2. HIV disclosure to 
the child 
3. Caregiver 
knowledge of ARV 
medication 
Forgetfulness (52.3%) 
Medication fatigue (26.2%) 
Caregiver lack of privacy to 
administer medication (14.3%) 
Caregiver illness (11.9%) 
Other (7.14%) – not at home, 




15 urban sites in 
US and Puerto 
Rico 
 












45% children who 
reported missing 1 
dose in past 7 days 





Load defined as 
having a viral load < 
400 copies/ml) 
By youth self-report: 
28% missed 1 dose in 




report , 22% missed 1 
dose in last 7 days  
1. Age 










Not available / not 
done  



















Not available / not 
done  








Subjected to all 3 
measures – 24.6% 
Good Adherence 
 
Not available / not 
done  
1. ARV side-effects 
2. Missed taking 
ARVs in six months 
period 
3. Monthly household 
income 
4. Affording 
transportation to the 
clinic 
 







































Not available / not 
done  
92% Full Adherence 3 
Day Recall, and 83% 
Full Adherence 30 Day 
Recall 
94% Full Adherence 
 
 
87% mean adherence 
Not available / not 
done 
1. Problems in 
community 
2. Problem with 
giving mediation to 
child 
3. Forgetting to give 
medication 
4. Giving late doses / 
missing doses 
Food insecurity (68%) 

















report one month 
recall 
Not available / not 
done 
78.6% had adherence 
>95% 




2. HIV Status 
disclosed to the child 
3.Caregiver ART 
knowledge 
4. Distance from 
health facility 
5. Caregiver’s 
educational status  




Child refusal (19.3%) 
Lack of transport (19.1%) 
Run out of pills (13.2%) 
Caregiver ill (5.5%) 
Child ill (3.2%) 
Pill burden (4.3%) 
Side-effects (4.3%) 
Taste of drugs (1.8%) 
Other (0.9%) 

















13% of the cohort 
had Viral load Failure 




(Viral load failure 
defined as having a 
viral load > 1000 
copies / ml) 
92% mean adherence 
before viral load failure 
for children 
experiencing viral load 
failure 
98% mean adherence 
for those without viral 
load failure 
88.3% good adherence 
 
1. Poor adherence 
by assessed by 
announced pill 
count  




Not available / not 
done 
Ran out of meds due to delayed 
clinic visits (29%) 
Child forgot (21%) 






















Child self-report  
 
89.8% (3 day Recall) 
84.4% (4 Week Recall) 
 
3. Missed a dose 
in 24 weeks since 



































load defined as 
having a viral load < 
50 copies/ml) 
92.6% Full Adherence 




77.2% Full Adherence 
reported by adolescents 
1. Alcohol/other 




pharmacy – less 
than 33 days 
being the median 
interval  
1. Anxiety score less 
than 8 at HAD of 
caregivers  
2. Children who had 
HIV diagnosis as a 
result of family 
screening 










Not available / not 
done 
Not available / not 
done 
Not available / not 
done 
Not available /not 
done 
Side-effects  
Size of tablets 
Poor taste of medicine 
Tablet regimen 
Taste of medication 







1.3 Problem Statement and Significance of the study 
 
The increased availability of ARVs has rapidly decreased the mortality and morbidity rates of 
HIV infected children globally. However, the clinical management of any chronic disease relies 
on the patient being adherent to their prescribed medication. Safety monitoring bloods such as 
viral load is currently the only reliable determinant for virologic failure, treatment failure and 
resistance in the treatment of HIV. In rural settings it is not always feasible and sustainable to 
monitor adherence with safety bloods. A reliable, valid and sustainable measure of adherence 
for children is crucial in combination with understanding the barriers for non-adherence and to 
design an intervention that will assist influential factors from the caregiver, child and healthcare 
workers related to non-adherence. 
Achieving optimal adherence to ARV’s in a rural paediatric population is challenging but 
critical to maintain for optimal clinical outcomes. Some of the challenges identified in the 
literature by caregivers, patients and clinical staff include: forgetfulness, non-disclosure to the 
child, child away from home, taste of drugs, treatment regimen complexities and primary 
caregiver support. Prior research indicates that the validity of adherence information is 
improved when multiple sources of information are used. Few studies have published clinical 
outcomes (viral load suppression) and other objectives methods (viz. pill count of returned 
drugs) to assess adherence in paediatrics.  
As shown in previous studies and according to the literature review conducted for this 
dissertation, many studies have collected data on reasons for non-adherence, predictors for 
virologic failure and non-adherence. However, there is a paucity of information available on 
interventions to improve assessment of medication adherence in children on ART. There is also 
a paucity of information on age-appropriate disclosure and the readiness of a child to take 
responsibility for their own health. HIV has now been classified as a chronic disease where 
antiretroviral medication needs to be taken for life with good adherence as a key marker for 
clinical success.  
If monthly pill count can be proven to be a reliable predictor of viral load, treatment and 
virological failure might be picked up by pharmacists or any other clinical team member before 
the annual monitoring safety bloods are to be done. This will ensure that adherence related 
barriers or challenges can be addressed and referred for emergent care. This will not only 
improve the quality of care that children receive, but will also have a positive impact on the 
quality of life for children on ART. 
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The current study will assess adherence outcomes using monthly pill counts, viral load along 
with self-reported reasons for non-adherence. 
1.4 Hypothesis 
 
Monthly adherence assessment by monthly pill count, when defined as >95%, is a reliable 
predictor of virological outcomes.  
 
1.5 Aim & Objectives 
 
1.5.1  Aim 
 
The aim of this study is to assess adherence to antiretroviral therapy in a rural paediatric cohort.  
 
1.5.2 Objectives  
 
1. The primary objective of this study is to evaluate the adherence in HIV-infected children in a 
rural community in KwaZulu-Natal, South Africa on antiretroviral treatment by comparing 
monthly pill count data with viral load. 
2. The secondary objective is to identify reasons for non-adherence as reported by the patients 
or caregiver themselves on the pill count CRF plate 022. 
3. The third objective is to analyse treatment regimens and any single drug or complete switches 
to determine if virological failure and / or medication side-effects can be linked to non-
adherence 
 
1.6 Conceptual framework 
 
Medication adherence is defined as the level to which a patient complies with his / her  health 
care management plan and dosing schedule of any prescribed medicine treatment (12). 
Traditionally, for a patient to achieve full adherence and maintain good clinical outcomes, the 
patient has to take more than 95% of the prescribed medication regimen (26, 27).  
Defining, measuring and maintaining medication adherence in a paediatric population is a 
challenge for both the healthcare providing team and the caregivers. Most of the paediatric 
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patients are taken care of by caregivers other than their biological parents, which results in the 
caregiver having to take the responsibility to adhere to the antiretroviral treatment program. 
Therefore the factors influencing the ability of the paediatric to adhere to the prescribed ART 












Figure 2: Factors influencing adherence 
Caregiver status often changes as elderly caregivers pass away and the paediatric patient are left 
to be taken care of by another family member or friend (29). This causes confusion as the new 
caregiver might not have the necessary knowledge on HIV and antiretroviral treatment.  
As caregiver of the paediatric patient they do not themselves always understand the disease 
progression of HIV or the working mechanism of the antiretroviral medication (22, 43).  
Paediatric related factors include forgetfulness, not wanting to take the medication, vomiting, 
running out of medication, non-disclosure, pill burden or feeling self-conscious / uncomfortable 
to take their ART in front of friends (19, 22, 43, 55).  
For the paediatric patient to collect the medication they often have to travel with public 
transport. Financially this is not always possible and as a result they miss their scheduled 




























experiencing financial strain, this often can cause food insecurity which may have a negative 
impact on adherence (43).                                                                                
Poor taste of liquid formulations or changing the antiretroviral treatment regimen causes the 
paediatric patient to refuse to take the medication (43). Having to take at least 5 tablets per day 
is burdensome and difficult to remember. Side-effects caused by the antiretroviral medication is 
often a fear for the paediatric patient. This leads to them refusing to take the medication. 
All of these factors have a negative impact on adherence to antiretroviral medication. To 






























CHAPTER 2: METHODS 
2.1 Study Design 
 
This is a retrospective review of routinely collected data from a paediatric cohort within the 
Centre for the AIDS Programme of Research in South Africa (CAPRISA) 052 AIDS Treatment 
Program, for the period of June 2008 – September 2013. However, this study only analysed 
monthly adherence data by pill count and virologic outcomes for the first 24 months on ART. 
This study formed part of service provision partially funded by the U.S. President's Emergency 
Plan for AIDS Relief (PEPfAR). 
 
2.2 Study area 
 
This CAPRISA 052 AIDS Treatment Program was conducted at the CAPRISA Vulindlela 
Clinic in rural KwaZulu-Natal, South Africa.  
 
2.3 Sample population 
 
Since the inception of the Vulindlela CAPRISA 052 AIDS Treatment Program in June 2008, a 
total number of 117 HIV infected children (<18years at time of enrolment) were screened for 
this treatment program, 79 children were enrolled, however only 78 children were initiated on 
ART during this period and were included in this analysis. The children enrolled into the 
treatment program were either ARV naïve, treatment interrupted and restarted at the study clinic 
or on treatment continuation after transfer into the treatment programme from surrounding local 
clinics. 
 
2.4 Inclusion / Exclusion Criteria 
 
Inclusion Criteria:  
Children were initiated on treatment if they met the following inclusion criteria in accordance 
with national paediatric treatment guidelines operational at the time:  
In 2004: 
1. Recurrent hospitalisations for HIV-related disease or,  
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2. WHO stage 2 or 3 disease or,  
3. CD4 percentage < 20 for those children <18 months or  
4. CD4 percentage <15 for those children >18 months.  
In 2010: 
1. All children <1 year should be started on ART 
2. Children 1 – 5 years of age: Symptomatic (stage3 or 4) or CD4 ≤ 25 % or CD4 absolute count 
< 750 cells/mm3 
3. Children ≥ 5 years: Symptomatic (stage III or IV) or CD4 < 350 cells/ mm3 
Exclusion: Criteria  
Children who received a 052 participant identification number at screening but never initiated 
on antiretroviral treatment were excluded from this analysis. 
 
2.5 Data Collection 
 
During the five year follow up period of the children enrolled into the CAPRISA 052 AIDS 
Treatment Program, routinely collected data at each scheduled / unscheduled study visit 
included: monthly pill counts, self-reported reasons for missing doses, clinical monitoring and 
safety bloods (CD4 and Viral Load).  
Baseline demographics collected at screening included age, gender, WHO staging, previous 
ART exposure, tuberculosis (TB) status and treatment history, CD4 count, viral load and the 
ART regimen on which they were enrolled. The type of primary caregiver and parent status 
were also collected.  
Screening and enrolment visits included comprehensive counselling of the primary caregiver 
emphasizing the reasons for starting ART, accentuating the importance of maintaining 
adherence, discussion of possible ARV side-effects, responsibility of the primary caregiver, and 
disclosure.  At every monthly visit, weight, height and TB status were collected. Blood samples 
were collected every 6 months to assess CD4 count, viral load, fasting cholesterol, liver 
function, glucose and triglycerides. These data were documented on the relevant Case Report 
Forms (CRFs) and data faxed for safe storage on the CAPRISA data base.  
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Self-reported measures were used to collect reasons reported for non-adherence and children 
were requested to return any extra / unused medication at each scheduled / unscheduled visit for 
completion of the pill count. Using pill count and syrup return data, monthly adherence 
estimates for each child from enrolment to study exit were collected together with any treatment 
regimens and / or any single drug or complete switches to determine if virological failure and / 
or medication side-effects could be linked to non-adherence. Al medication returns whether 
tablets or syrups are referred to as pill count data in this dissertation. 
At enrolment and at monthly follow-up visits the following relevant data were collected on 
CRFs–  
1. Plate #010 Enrolment and Monthly Follow-up (Appendix J): Height and Weight 
2. Plate #011 Enrolment and Monthly Follow-up (Appendix K): ART Regimen 
 commencement and changes, reason for any changes, dates of commencement and 
 changes 
3. Plate #012 / Plate #022 Pill count (Appendix L & M): Visit date; ARV treatment; Drug 
 Type; Drugs returned, lost or reported as remaining at home; and any reasons for 
 missing doses 
4. Plate #013 Laboratory Results (Appendix N): HIV test, CD4 results and Viral Load 
 results 
Before the commencement of the CAPRISA 052 AIDS Treatment Program all the relevant 
CRFs have been validated. The following processes were followed for this validation:  
1. All CRFs were designed depending on the type of information required for the 
 CAPRISA 052 AIDS Treatment Program.  
2. The CRFs containing laboratory information such as viral loads and CD4 counts were 
 drafted by the data management team and sent to the CAPRISA Vulindlela site and 
 laboratory. This was to ensure and verify that the units were correct for each laboratory 
 variable, that sufficient blocks have been allocated for data to be captured and if skip 
 patterns existed where needed. This was not piloted but assessed at site training before 
 approval of the final set. 
3. For behavioural data or data where a response was required the first draft of the CRFs 
 was done by the study team and pharmacy were applicable.  
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4. At the CRFs training, all other issues with the CRFs were discussed and resolved before 
 edits were finalized. 
5. Edit checks were also programmed for certain variables in the Data fax data base to 
 pick up certain obvious errors – like age – if a study is 0 - 18 years only then ages 
 entered above or below this are immediately picked up as Quality Check errors when 
 the forms are faxed in. 
Antiretroviral medication was prescribed and dispensed in accordance with the South African 
National Department of Health (SA NDoH) Antiretroviral Treatment Guidelines (Appendix D-
I) for children according to their current weight. If the child sent a relative or sibling to collect 
their ART due to school attendance, the weight from the previous visit was used. ARV drugs 
available at the facility included: efavirenz, stavudine, lamivudine, abacavir, didanosine, 
zidovudine and lopinavir/ritonavir.  
At each scheduled / unscheduled study visit the pharmacist documented the quantity of 
medication returned, quantity of medication reported as lost, quantity of medication reported at 
home and the quantity of medication dispensed at the current visit on the pill count CRFs. 
Adherence was calculated monthly during the service provision by using the computerised i-
DART (Intelligent Dispensing of Antiretroviral Treatment) program. The i-DART program 
included the name of the child, date of birth, sex, ART start date, treatment history according to 
ART active ingredient and a computerised adherence percentage. This calculation took into 
account the number of days passed since the last clinic visit / ART collection, quantity of 
medication dispensed at the last visit and the quantity of medication returned at the current visit. 
The i-DART program also indicated to the pharmacist the amount of medication that had to be 
dispensed to the child to last till the next scheduled appointment which served as a secondary 
check for accuracy. This minimized the possibility of children running out of any medication. If 
by any chance they ran out of medication they were advised to return to the pharmacy for an 
additional supply to last till their next scheduled appointment.  
Monthly adherence support counselling was offered as needed to children and their caregivers 
when pharmacy adherence calculations by pill count was below 95%. Tools such as pillboxes 
and cell phone clock reminders were introduced in an attempt to improve adherence with 
reminders proposed to be set to coincide with a daily activity like a television program or 
brushing of teeth in the morning. The medication labels included medication instructions in both 
isiZulu and English. To assist with possible language barriers and to ensure that medication 
instructions were understood, pharmacy had an isiZulu pharmacist assistant translating 
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information to the children and their caregivers. Pharmacists also learnt the basic dispensing 
isiZulu in events where the pharmacist’s assistant was not able to assist. 
Additional adherence counselling and support was provided if treatment failure was suspected. 
Treatment failure was defined as having a detectable viral load >1000 copies/ml, tested three 
months apart, despite good adherence. At this point, children were then switched to an 
appropriate second line regimen.  In accordance with the SA NDoH Antiretroviral Treatment 
Guidelines in 2004, the limit of detection of viral load was 400 copies/ml. This was 
subsequently updated in March 2013, in accordance with available test standards, to 50 
copies/ml. However, viral load data in this study assessed at months 6, 12 and 24 was based on 
the limit of detection of 400 copies/ml for consistency.  
Any changes to the antiretroviral regimen and reasons for this, were captured on plate #011 
(Appendix K) throughout the study and these changes were explained to the children and 
primary caregivers. Counselling for the updated regimen and the understanding of this regimen 
and its dosing intervals were emphasized before dispensation.  
Children and their caregivers had the knowledge to distinguish between the different ARVs they 
were taking, its generic names, dosing intervals, colour and shape of tablets and what the 
medication containers looked like. When they collected medication from other local primary 
health care clinics, when visiting family in other areas, they were advised to take their empty 
containers with and verify that the ARVs dispensed to them were exactly the same as the usual. 
When drugs were received from different pharmaceutical suppliers we informed the children 
and showed them that the active ingredients were the same. This enabled the children to query 
any unknown medication received from us or any other clinic. 
Efforts to empower the children and enabling them to take the responsibility for their ART 
outcomes, adherence and overall health were constantly being made by all the pharmacists. 
 
2.6 Data Management 
 
All required CRFs were completed at each scheduled / unscheduled study visit during the five 
year follow up period of all children initiated on ART. These completed CRFs were data faxed 
and stored in the CAPRISA data base. This made the data easily accessible for reviewing of 
completeness, quality and validity.  
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To ensure validity and reliability of data before commencement of analysis, a full file review of 
all the participants files have been conducted by the masters’ candidate. Any outstanding or 
incomplete CRFs have been completed and re-faxed.  
 During the file review, the pill count plate had to be checked / verified for the following: 
1. Participant identification number is accurate 
2. Date and visit code needs to be filled 
3. Ensure that correct treatment code is filled  
4. Medication returned, reported at home and dispensed on day of the visit should be filled 
5. The drug type should correspond with the quantity of medication dispensed e.g. Drug 
 type 2 = liquid, quantity dispensed cannot be 30, Drug type 1 = tablets cannot be 240. 
Safety monitoring bloods, such as VL and CD4, were taken at enrolment, month six, annually 
and additionally when requested by the study clinician or as per the SA NDoH ART guidelines 
at the time. Original copies of all safety blood tests were filed in the participant file. This 
information was captured on an Excel spreadsheet to highlight any missing data. Information 
mainly included in this spreadsheet were: 
1. Participant Identification number,  
2. Sex,  
3. Date of Birth,  
4. Date started on antiretroviral medication,  
5. Regimen started on,  
6. Any regimen changes including date and reason,  
7. CD4% and CD4 count and  
8. Viral load results. 
The completed excel spreadsheet was sent to the statistician to verify against the CAPRISA data 
base. After the file review has been conducted, confirmation from the statistician were received 




2.7 Data Analysis 
 
Statistical Analysis was performed using SAS Version 9.4 (SAS Institute, Cary, North 
Carolina).  
Table 2: Variables for analysis 
Variable Variable Type Descriptive Measures 
Age Quantitative (Continuous) Mean with Standard Deviation or 
Median / Interquartile Range 










Weight Quantitative Mean with Standard Deviation or 
Median with Interquartile Range 
BMI Quantitative Mean with Standard Deviation or 
Median with Interquartile Range 
CD4 Quantitative Median with Interquartile Range 
Viral load Quantitative Mean with Standard Deviation 
Reported 
challenges 
Qualitative Frequency or Summary 
Adherence 
Monthly 








Descriptive statistics were used to describe the baseline characteristics. Baseline demographics 
included the characteristics of the child; age, gender, WHO staging, previous ART exposure, 
TB status and treatment, CD4 count, CD4%, viral load and the ART regimen they were enrolled 
on. The category of primary caregiver and parent status were also collected at enrolment. 
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Sensitivity and specificity analysis were conducted to check the accuracy of the pill count 
measure when compared to the viral load measure (gold standard).  McNemar’s chi-square test 
for dependent samples was used to determine whether there is a difference in the proportion of 
high/low adherers when measured using pill count or viral load. Generalised estimating 
equations were used to identify predictors associated with undetectable viral load (<400 
copies/ml) over time. Viral load was categorized into a binary variable (detectable vs. 
undetectable) and used as a dependent variable. The explanatory variables included in the model 
were adherence >95%, age, gender, WHO stage, whether parent(s) is alive and primary 
caregiver. These variables were used to assess whether they, predict or influence viral load 
suppression or detectable viral load. Odds Ratios with a 95% Confidence Interval were 
calculated in the univariate and multivariate analyses. Variables with an Odds Ratio > 1 or a p-
value less than 0.05 were considered to be statistically significant, associated with having an 
undetectable viral load.  
Monthly adherence have been calculated and the average adherence for each patient have been 
categorized into (high ≥95% and low <95%). For paediatrics who received syrups in their 
regimen, a leeway of 5% has been added due to difficulty in administrating syrups, 
wastage/spillage and possible incorrect dosing quantity when syringes were being used. 
Adherence percentage for syrup formulations was calculated as follows: 
Volume of syrup dispensed at last clinic visit – Volume of syrup returned at current visit x 100                                    
Volume of syrup (ml) that should have been ingested between visits 
Adherence percentage for tablet formulations was calculated as follows:  
Number of tablets dispensed at the last clinic visit – Number of tablets returned at current visit x 100 
Number of tablets that should have been ingested between visits 
The denominator accounts for the time elapsed between clinic visits. 
 
2.8 Ethical Considerations and confidentiality 
Postgraduate approval and UKZN Biomedical Research Ethics Committee was received before 
the analyses of this study began (Reference #: BE069/15, E248/05).  
The data extracted from the data base for this study was routinely collected in the CAPRISA 
052 AIDS Treatment Program which initiated in June 2008. No paediatric patient names were 
documented on any of the Case Report Forms. Each child received a unique participant 
identification number at enrolment into the treatment program. That ensured that no linkage 
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between participant identification numbers and names could be made by the statistician 
assisting with the analyses. There was no need for informed consent because the data that were 
used do not contain any identifying patient information and the study was a secondary analysis.  
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This study retrospectively assessed adherence outcomes using monthly pill count data, viral 
load data and reasons reported for non-adherence in a paediatric cohort in KwaZulu-Natal, 
South Africa. Between 2008 and 2013, 78 children, mean age of 7.1 years, were enrolled in the 
CAPRISA 052 AIDS Treatment Program. Monthly adherence by pill count was categorized into 
high (≥95%) and low (<95%) categories.  Overall median monthly adherence to treatment was 
87.8% at month six, 88.9% at month 12 and 90.8% at month 24. The proportion of children with 
an undetectable viral load (< 400 copies/ml) were 84.0% (63/74) at month six, 86.6% (58/67) at 
month 12, and 84.5% (49/58) at month 24. Multivariate analysis demonstrated that the baseline 
WHO stage, primary caregiver status, primary caregiver being the recipient of any financial 
grant and overall pill count were significant predictors of viral load suppression.  In conclusion, 
this treatment program demonstrated sustained high adherence to treatment over a two year 
period, with pill count being a good tool to measure adherence and viral load assessment 







According to the World Health Organisation (WHO) in 2014, 2.6 million children (<15 years) 
were living with Human Immunodeficiency Virus (HIV) globally, 220 000 children were newly 
infected with HIV and 150 000 children demised due to Acquired Immune Deficiency 
Syndrome (AIDS)-related illnesses (1). Sub-Saharan Africa remains the region with the highest 
number of children living with HIV, with a documented 2.3 million children living with HIV in 
2014, and only 30% of these children (age 0 – 14 years) accessing antiretroviral treatment (2). 
In South Africa, of the 360000 reported HIV infected from 2013 statistics (3), only 156700 were 
initiated on ART (4). 
ART, when taken consistently, aims to rapidly reduce the viral load of patients and the goal of 
treatment is to maintain an undetectable viral load and to provide sustainable AIDS free 
survival. (5). Good adherence has in previous studies been identified as a positive predictor of 
good clinical outcomes and therapeutic success in children, adolescents and adults (6-8). For a 
patient to achieve virologic suppression and maintain good clinical outcomes more than 95% of 
the monthly prescribed HIV medication must be ingested (8-10). Whether the > 95% cut off is 
appropriate for paediatric patients is unclear , however a prospective observational study, which 
explored the agreement between pill count and viral load in adult patients on ART, found that a 
95% cut-off for adherence by pill count had a closer relationship with viral load outcomes than a 
90% cut-off (11). A secondary analysis conducted in a South-African paediatric cohort (children 
< 2years of age) concluded that adherence by medication return of < 85% was associated with 
an increased likelihood of poor viral suppression. (12).   
Although comprehensive treatment guidelines are available in South Africa, achieving optimal 
adherence to ART (>95% of doses per month ingested) and maintaining virological suppression 
in a paediatric cohort remains challenging. With viral load assessed every six months or 
annually as per the National Department of Health Paediatric HIV Treatment Guidelines (13), 
the emphasis on finding an alternate interim (between viral load monitoring) adherence 
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monitoring tool, particularly in rural areas, is indispensable. There is a paucity of information 
and insufficient guidance on how to measure and improve adherence in South Africa for this 
population. 
Different adherence monitoring methods used by other studies in South Africa included self-
report by caregivers, medication return assessments, medication event monitoring systems, 
using visual analog scales, and pharmacy refill data (14-16). Amongst these methods, 
medication return has been shown to have a positive correlation with virologic response in 
children (12, 15). 
Defining, measuring and maintaining medication adherence in a paediatric population is 
challenging for both the healthcare provider and the caregivers. Sustaining drug supply of 
paediatric formulations, the relationship between the healthcare provider and the caregiver, and 
the possibility that the same healthcare provider might not examine you at each visit are 
amongst the challenges that healthcare providers face in supporting medication adherence (17).  
Some children are taken care of by caregivers other than their biological parents (18), which 
results in the caregiver having to take the responsibility to ensure the child is adherent to 
antiretroviral treatment. Therefore the factors influencing the ability of the child to adhere to the 
prescribed regimen is also linked to challenges faced by the caregiver supporting the child (19, 
20).  
Barriers to adherence identified by caregivers, patients and clinical staff include social 
circumstances, non-disclosure of HIV status to the child, psychosocial issues, treatment regimen 
complexities, unpalatable medicine, forgetfulness by either the primary caregiver or the children 
themselves,  medication side-effects, and lack of primary caregiver support (6, 19, 21). These 
factors can all potentially negatively impact adherence to antiretroviral (ARV) medication and 
to improve the clinical and virological outcomes of the paediatric patients, these factors need to 
be assessed, and where necessary, addressed. 
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Without a standardized measure for medication adherence it is difficult to estimate true 
adherence in a paediatric cohort. Self-reported measures remain the most common used method 
to determine adherence, but it mainly relies on patient or caregiver memory and may result in 
over- estimation of actual adherence (10, 22).  
The present study evaluates medication adherence in HIV-infected children on ART in a rural 
South African setting by comparing monthly pill count data with virological outcomes and 
identifying reasons for non-adherence as reported by the patients or caregiver themselves at 
each visit. The aim is to assess adherence outcomes for HIV infected children on ART in a rural 
community and also to assist in determining whether monthly pill count can be defined as both 
a reliable measure of medication adherence in this population and as an independent predictor of 
virological failure to assist in resource constrained rural settings that may not have easy access 
to frequent viral load monitoring. 
 
METHODS 
Study design, setting and participants 
This was a retrospective analysis of routinely collected data from a paediatric cohort within the 
Centre for the AIDS Programme of Research in South Africa (CAPRISA) 052 AIDS Treatment 
programme, for the period June 2008 to September 2013, in rural KwaZulu-Natal, South Africa. 
The treatment program, funded by the President's Emergency Plan for AIDS Relief (PEPfAR), 
offered programmatic HIV care to children as per the current SA National paediatric treatment 
guidelines. Children were eligible to start treatment if they met the following inclusion criteria: 
Recurrent hospitalisations for HIV-related disease or, WHO stage 2 or 3 disease irrespective of 
CD4% or, CD4% less than 20 for those younger than 18 months or CD4% less than 15 for 
children 18 months and older. The children enrolled into the treatment program were either 
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ARV naïve, ART treatment interrupted requiring ART re-initiation, or requiring treatment 
continuation after transfer in from surrounding local clinics. 
Data collection 
Baseline demographics collected at screening included age, gender, WHO staging, previous 
ART exposure, tuberculosis (TB) status and treatment history, CD4 count, viral load and the 
ART regimen they were enrolled on. The type of primary caregiver and parent status were also 
collected. Screening and enrolment visits included comprehensive counselling of the primary 
caregiver, emphasizing the reasons for starting antiretroviral treatment through counselling the 
primary caregiver, accentuating the importance of maintaining adherence, discussion of possible 
ARV side-effects, responsibility of the primary caregiver, and disclosure.  Tools such as 
pillboxes and cell phone clock reminders were introduced in an attempt to improve adherence 
with reminders proposed to be set to coincide with a daily activity like a television program or 
brushing of teeth in the morning. 
 At every monthly visit, weight, height and TB status was documented. Blood samples were 
collected every 6 months to assess CD4 count, viral load, fasting cholesterol, liver function, 
glucose and triglycerides.  Additional adherence counselling and support was provided if 
treatment failure was suspected. Treatment failure was defined as having a detectable viral load 
>1000 copies/ml, tested three months apart, despite good adherence. At this point, children were 
then switched to an appropriate second line regimen.  In accordance with the South African 
National Department of Health (SA NDoH) Antiretroviral treatment guidelines in 2004, the 
limit of detection of viral load was 400 copies/ml. This was subsequently updated in March 
2013, in accordance with available test standards, to 50 copies/ml. However, viral load data in 
this study assessed at months 6, 12 and 24 was based on the limit of detection of 400 copies/ml 
for consistency. Drug regimen changes and/or single drug switches, for virological failure or 
medication intolerance respectively, was assessed. 
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Using pill count and syrup volume return data, monthly adherence estimates were calculated for 
each patient from enrolment to study exit.  All medication returns data, whether tablets or 
syrups, are referred to as pill count data in this manuscript.  
Caregiver or child self-report was used to ascertain reasons for missing doses (patient ran out of 
pills, clinic ran out of medicine, caregiver status changed, cannot recall, caregiver/patient forgot, 
caregiver did not supervise, felt too ill, cannot recall/denies missing a dose, unknown/remaining 
medication not returned at visit, or any other reason). Monthly adherence support counselling 
was offered as needed to children and their caregivers when pharmacy adherence calculations 
by pill count was below 95%. For the purpose of this study, monthly adherence by pill count 
was categorized into high if more than or equal to 95% and low if below<95%. For children 
receiving syrups in their regimen, a 5% volume margin of error was allowed to accommodate  
challenges in administrating syrups, wastage/spillage and possible incorrect dosing volume  
with doses administered orally dosing by syringe. 
Adherence percentage for syrup formulations was calculated as follows: 
Volume of syrup dispensed at last clinic visit – Volume of syrup returned at current visit   x 100                                    
Volume of syrup (ml) that should have been ingested from between visits 
 
Adherence percentage for tablet formulations was calculated as follows:  
Number of tablets dispensed at the last clinic visit – Number of tablets returned at current visit    
x 100 
                                      Number of tablets that should have been ingested between visits 





Descriptive statistics were used to describe the baseline characteristics. Sensitivity and 
specificity were calculated for pill count adherence (≥ 95% vs. <95%) using viral load (<400 vs. 
≥ 400 copies/ml) as the gold standard. McNemar’s test for dependent samples was used to 
determine whether there was a difference in the proportion of high/low adherers when measured 
using pill count and viral load. Generalised estimating equations were used to identify 
predictors associated with undetectable viral (<400 copies/ml) load over time. The variables 
included in the multivariate model were adherence age, gender, WHO stage, whether guardian 
was the recipient of any grant and primary caregiver status. All statistical tests were conducted 
at a 5% level of significance and analyses were performed using SAS Version 9.4 (SAS 
Institute, Cary, North Carolina). 
The Biomedical Research Ethics Committee of the University of KwaZulu-Natal reviewed and 
approved this study (Reference #: BE069/15, E248/05). 
 
RESULTS 
Baseline Demographics and clinical characteristics 
Since the inception of the CAPRISA 052 AIDS Treatment Program in June 2008, a total 
number of 117 children were screened and 79 (<18 years at time of enrolment) were enrolled in 
the programme with 78 initiated on treatment. The age range for these patients was six months – 
13 years. Baseline demographics and relevant clinical characteristics are shown in Table 1. 
 
Adherence by pill count  
At programme enrolment and depending on age and weight, 54 children received formulations 
consisting of tablets and syrups, whilst 24 children received tablet only regimens. The 
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proportion of children who achieved adherence >95% at month six, 12 and 24 was 32.3%, 
35.8% and 34.5% respectively. Overall median monthly adherence was 87.8% (interquartile 
range (IQR): 71.0-99.6%) at month six, 88.9% (IQR: 77.1-99.8%) at month 12 and 90.8% (IQR: 
79.1-99.2%) at month 24. Median monthly adherence by pill count remained above 85% 
throughout the follow up period (Figure 1).  
Overall reasons reported for missing doses by either the caregiver present at the visit or the 
patient themselves were: forgetfulness of the caregiver / paediatric (31.0%), felt too ill (15.0%), 
caregiver did not supervise (13.4%), cannot recall / denies missing any dose (12.0%), caregiver 
status changed (8.7%), unknown / remaining medication not returned at visit (8.3%), patient ran 
out of pills (4.5%), change in daily routine / away from home (4.5%), other (2.4%) and side- 
effects (0.2%),  (Figure 2). Other reasons reported for non-adherence were extra pills in 
container, child refused to take medication, troubled child, does not want to take syrups and 
caregiver reports no food at home. 
 
Clinical Response to Antiretroviral Treatment 
The proportion of children with an undetectable viral load (< 400 copies/ml) were 84.0% 
(63/74) at month six, 86.6% (58/67) at month 12, and 84.5% (49/58) at month 24. At the end of 
the follow-up period three children had died, one between month 0 and six of follow-up, and 
two between month six and 12 of follow-up.  A total of 17 children were transferred out to their 
local primary health care clinics, during the 24 month period, for ongoing care.  
During the two year follow-up period, five children were switched to second line treatment due 
to treatment failure. Treatment failure for four children was confirmed at their month 12 visit 
and one child experienced treatment failure at month 24. The overall median adherence for 
these 5 children at month six, 12 and 24 was 95.1%, 80.3% and 100% respectively. Viral load 
suppression was achieved after regimen change for all five children, however one child had a 
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detectable viral load 11 months after the regimen switch due to non-adherence. Three other 
children had a single-drug switch on first line treatment due to laboratory / clinical toxicity (two 
were for hyperlactatemia and one for suspected abacavir allergy).  
 
Agreement between adherence by pill count and viral load 
Sensitivity and specificity for adherence by pill count and viral load (gold standard) was low. 
We found that 33.9%, 36.2% and 30.6% of children who were truly adherent by pill count were 
classified as adherent at month six, 12 and 24 respectively (Table 2). 
 
Predictors of viral load suppression  
In multivariate analysis (Table 3) children with an overall adherence > 95% were 3.56 times 
more likely to have an undetectable viral load than those with adherence <95%. Children with 
WHO stage 3 or 4 were 2.70 times more likely to have an undetectable viral load as compared 
with those with WHO stage 1 or 2 at enrolment. Where the primary caregiver was a family 
member other than a biological parent, children were more likely to suppress viral load as 
compared to when the parent was the caregiver. If the guardian was a recipient of any grant the 
child was 4.05 times more likely to have an undetectable viral load. Age and gender were not 
predictive of viral suppression. 
 
DISCUSSION 
Our study found that overall adherence measured by pill count remained above 85% throughout 
a two year follow-up period and good clinical outcomes were achieved in this rural paediatric 
ART cohort. Children with an overall adherence > 95% were nearly four times more likely to 
have an undetectable viral load. However, in our study, sensitivity of pill count to predict 
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adherence by using viral load as a gold standard was very low and this may possibly be 
attributable to the > 95% definition for high adherence.  The sensitivity and specificity of  
adherence measures are  significantly influenced by the cut-off points chosen by investigators to 
define the level of adherence (23).   Although, the pill count is an excellent measure for 
healthcare workers to assess adherence more frequently, the gold standard for assessment of 
adherence to treatment remains the viral load measurement.  This highlights the significant 
challenges in managing adherence on HIV treatment, where the outcome (viral load 
suppression) measured months after treatment start is indicative of therapeutic success or failure 
but a less invasive/expensive real-time measure to accurately monitor treatment remains elusive.  
Pharmacy adherence measures such as returned pill count can play an important role in 
monitoring adherence (24), especially to confirm whether the patient understands their ARV 
regimen dosing and if good clinical outcomes can be expected in between annual safety bloods 
being done. However studies suggest that multiple measures, and not pill count alone, should be 
used to predict adherence to maximize the reliability and validity of data collected (21, 25). A 
study in New Jersey, USA found an association between virologic response and the 
concordance of all three measurements of adherence: pharmacy refill, caregiver self-report and 
clinic appointment data (26). In addition the use of monthly pill count in our setting assisted in 
identifying adherence related barriers or challenges in between scheduled viral load monitoring 
bloods enabling these barriers to be addressed by referral for additional care to the counsellors 
and clinicians. Similarly to us, other rural cohorts in Africa also found a positive association 
between medications return / pill count and viral load (15, 27). 
Early literature suggested that adherence of > 95% should be maintained for a patient to achieve 
virologic suppression and good clinical outcomes (9), and this percentage is often used in 
practice when assessing a patients’ adherence.  However, the association between adherence and 
virologic response in other studies is not always consistent (7, 10, 26). In our study the 
proportion of children achieving an undetectable viral load was similar to that of the children at 
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the Sinikethemba Clinic, in rural Kwa-Zulu Natal where 84% of the children had an 
undetectable viral load at month six and 80.3% children had an undetectable viral load at month 
12 (14). Of the children in a prospective cohort study in Cape Town 78% achieved undetectable 
viral load (15) and in Kigali, Rwanda, an undetectable viral load was attained for 82.8% 
children (28). In the Cape Town cohort the percentage of children achieving medication return 
adherence > 90% was 79%, and approximately 58% of the children achieved an adherence 
above >95% (15). Another prospective study in Uganda showed that over the 12 months of 
treatment about 40% of the children consistently had a detectable viral load (29). Alarmingly 
children from New Jersey had poor virologic response to antiretroviral treatment with not even 
40% of the children achieving an undetectable viral load of < 400 copies/ml (26). However, that 
study only used a single-point measurement for viral load to compare virologic outcomes with 
adherence. In our study, treatment failure and poor tolerance to ART resulting in drug switches 
was rare. 
An important predictor of having an undetectable viral load in the present study was having 
WHO stage 3 and 4 at baseline. Similarly, Ethiopian children with baseline WHO stage 3 and 4 
were more adherent to their treatment (30) as were children with WHO stage 2 or 3 in Cape 
Town (15). It is possible that children with a more severe disease and their primary caregivers 
are more motivated to be adherent to treatment in our setting. In contrast, a South American 
study demonstrated that  experiencing a WHO stage 3 and 4 event during the course of 
treatment was positively associated with  viral load > 5000 copies / ml (31). 
Several factors may have played a role in the less than optimal adherence demonstrated by some 
children in our cohort. Some were on antiretroviral treatment for longer periods than those in 
other studies (10), and treatment fatigue may have set in. Our adherence data was collected 
monthly or two monthly as opposed to 3-day and 7-day recall periods utilised in other studies 
which may be easier to remember (29, 32). Poor adherence by pill count can be influenced by 
errors in measuring and administering liquid formulations. Caregivers might not be able to 
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administer the correct quantity, they may not have a syringe available for administration and 
spillages can happen during administration. Pill dumping in toilets or outside bins at the clinic 
has occurred, infrequently, at our setting where children deliberately threw extra pills away 
before visiting the pharmacy in order to appear adherent. 
It is important to take into account the influence of the primary caregiver on adherence. In a 
Cape Town cohort a high percentage (88%) of mother’s were the primary caregiver (15) and 
both parents were alive for 72% of the Zambian children (27) as compared to the 42.9% of 
children in our cohort that have lost both their biological parents and about half of the cohort 
having a primary caregiver other than their biological parents. Our children were more likely to 
have an undetectable viral load if the primary caregiver was not the biological parent. In 
contrast to our findings, a study in Elandsdoorn in rural South Africa reported that children who 
did not have a parent as the primary caregiver were more likely to have virologic failure (33). 
The inconsistent results of the influence of the parent as the primary caregiver on adherence and 
virologic outcomes should be investigated. It is possible that the biological parents might not 
always be able to supervise the taking of ART treatment and therefore delegate the 
responsibility to the child themselves. This highlights the importance of counsellors establishing 
supportive relationships with caregiver and child, in understanding the child’s social 
circumstances, tailoring counselling messages and facilitating age-appropriate disclosure of the 
child’s HIV status to empower them to eventually take full responsibility for their own health, 
understanding the implications of poor adherence. 
Studies have also shown that the socio-economic status of the caregiver is associated with poor 
adherence (14, 15, 34, 35).  In our study children with caregivers who were the recipients of any 
grant were more likely to have an undetectable viral load. Similar findings in USA, Zambia and 
Tanzania showed higher income levels and monthly household income were positively 
associated with viral load suppression (36-38). Caregivers and children often had to make use of 
public transport to come to our clinic due to longer travelling distances. If they did not have the 
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money they missed their appointment dates and only came back once they had the available 
funds.   
Memory aids in our study consisted of weekly pillboxes and cell phone alarm reminders which 
were set to fit their daily routines. In an Ethiopian study the majority of caregivers (67.1%) 
reported that they were using their watches as a reminder (30). We assisted our caregivers and 
children in packing these weekly pill boxes during their visit at the pharmacy, labelling the daily 
or twice daily pill boxes with sun / moon pictograms, together with setting a cell phone alarm 
reminder. At the next contact visit they were to return the pill box together with any remaining 
tablets. However not all children liked the pill boxes as they were concerned it would raise 
unwanted questions from friends and other family members. In a rural setting the availability of 
cell phones is limited and when the primary caregiver is not at home at the time when the child 
has to take the medication, doses could be missed. The child might then be asleep when the 
caregiver returns home. After identification of this barrier we advised the children to find an 
alternative reminder, this included a television program or any activity which was repeated 
daily. This encouraged them to be more responsible for taking their own medication. To 
maintain continuity of care, the importance of a reliable secondary caregiver and handover of 
responsibilities when primary caregiver is not around was highlighted as a challenge in our 
cohort.  
In our cohort forgetfulness of the primary caregiver and / or the paediatric was reported as the 
most common reason for non-adherence, similar  to other  studies where forgetfulness by the 
caregiver was also distinctly recognised as a reason for non-adherence (19, 30, 32, 39). Other 
reasons for non-adherence that were similar to previous findings were that the child felt too ill 
to take medication, a change in daily routine or child ran out of medication (40, 41). In contrast 
to other studies, in our study side effects of antiretroviral medication reported as a reason for 
non-adherence was only 0.19% as compared to 16.3% and 4.3% in Ethiopian studies (40, 41) 
where side-effects of antiretroviral medication was found to be a predictor of adherence (37). In 
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our study comprehensive counselling included possible side-effects to expect and were advised 
to return to the clinic if any of these occurred for further management.  
This study has several limitations. HIV disclosure and its correlation with adherence outcomes 
was not measured in our study. Pharmacy refill data as an adherence measure was not assessed. 
Not all medication was returned at each of the monthly visits as sometimes relatives were sent 
to collect medication which may affect accuracy of the adherence assessment. Self-reported 
reasons for non-adherence are subject to recall bias and a desire to please the provider. In 
addition, all children and caregivers knew what to expect at the visit which included the pill 
count and questioning about any discrepancies. However, in a cross-sectional study in Ethiopia 
the proportion of children achieving an adherence >95% by pill count was similar to ours 
(34.8% vs. 35.8%) (30). The difference, between our assessment of adherence and that of the 
Ethiopian study is that we collected monthly adherence data over 24 months, whereas their pill 
counts were unannounced and based on recall for the past seven days, but with very similar 
outcomes.  
Globally a standard definition for paediatric adherence and a reliable and valid measure of 
adherence is required for any future studies on paediatric adherence to ART in rural settings. 
While we used the traditional  accepted >95% adherence by pill count cut-point to define high 
adherers we found that lower levels of adherence still resulted in successful treatment outcomes. 
Little has been done to investigate sustainable interventions to improve medication adherence 
for children on ART. These interventions should be cognisant of all the possible factors 
influencing adherence including medication related factors, healthcare related factors, caregiver 
related factors and child related factors. Considering these factors, more research is needed to 
determine the effect that early age-appropriate disclosure in children has on their adherence. 
Continuous education is needed to make HIV infected children more responsible to take their 
own medication and where possible, to be less reliant on the primary caregiver.  
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In conclusion, this treatment program proved that high adherence in a rural paediatric cohort in 
South-Africa is possible. Secondly, although adherence of >95% by pill count was found to be 
associated with viral load suppression  and is a good, relatively easy method to monitor 
adherence at each contact visit,  assessment of viral load is still the best measure of treatment 
success and cannot be substituted.  
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Figure 2: Frequency of reasons for missing doses reported for non-adherence 
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 Table I: Baseline demographics and clinical characteristics 
Variable Overall (N=79) 
Demographics  
Age (years), mean ± SD  7.1±3.4 
No. of males, %(n) 55.7 (44)  
Weight (kg), median (IQR)* 22.0 (17.5 - 26.0) 
Which parent(s) alive, % (n)*  
Both 42.9 (33) 
Mother only 22.1 (17) 
Father only 10.4 (8) 
Neither 24.7 (19) 
Primary caregiver relationship, % (n)*  
Parent 51.9 (40) 
Family member 46.8 (36) 
Foster/surrogate parent 1.3 (1) 
Social financial support, % (n)*  
Child support grant  69.6 (55) 
Foster care grant 6.3 (5) 
Disability grant 2.5 (2) 
Child support & disability grant 1.3 (1) 
No grant 20.3 (16) 
ART/HIV  information, % (n)  
ARVs initiated in the past* 22.1 (17) 
Type of past ARVs, % (n)  
PMTCT 5.0 (4) 
Lifelong ART 16.5 (13) 
Current TB treatment** 9.2 (7) 
WHO stage of HIV disease, *  
stage 1 26.0 (20) 
stage 2 28.6 (22) 
stage 3 37.7 (29) 
stage 4 7.8 (6) 
CD4+ count(cells/mm3), median (IQR)† 278 (126-592) 
CD4%, median (IQR)** 12 (5.6-17.5) 
Viral load (log copies/mL, mean ± SD‡ 4.6±1.2 
ART Regimen, % (n)  
EFV/3TC/d4T 47.4 (37) 
EFV/3TC/ABC 34.1 (27) 
ABC/3TC/LPV/r 8.9 (7) 
EFV/3TC/LPV/r HD 8.9 (7) 
SD: Standard deviation, IQR: Interquartile Range, ARVs: Antiretroviral drugs, PMTCT: Prevention of 
Mother to Child Transmission, ART: Antiretroviral Treatment, TB: Tuberculosis, WHO: World Health 
Organization, EFV: efavirenz, 3TC: lamivudine, d4T: stavudine, ABC: abacavir, LPV/r: 
lopinavir/ritonavir, HD: half dose   

























Viral Load  
detectable  
(>400 copies/ml) 
Month 6 viral load (N=74) 
>95% 21 (33.9%) 3 (25.0%) 
<95% 41 (56.1%) 9 (75.0%) 
   
Sensitivity 33.9% 
Specificity 75.0% 
Month 12 viral load (N=67) 
>95% 21 (36.2%) 3 (33.3%) 
<95% 37 (63.8%) 6 (66.7%) 
   
Sensitivity 36.2% 
Specificity  66.7% 
Month 24 viral load (N=55)* 
>95% 15 (30.6%) 4 (66.7%) 





Table III: Factors associated with a viral load <400 copies/ml  
Variable Univariate Multivariate 
 OR 95% CI p-value OR 95% CI p-value 
Gender (ref=male) 
Female 1.44 0.77-2.70 0.258 1.31 0.63-2.71 0.472 
 
WHO stage (ref=1 or 2) 
Stage 3 or 4 2.90 1.33-6.34 0.008 2.70 1.05-6.92 0.038 
Guardian recipient of any grant? (ref=No) 
Yes 
3.11 1.52-6.34 0.002 4.05 1.74-9.42 0.001 
Primary caregiver (ref =Parent ) 
Family member 1.80 0.93-3.45 0.079 3.29 1.52-7.14 0.003 
       
CD4+ count (per 50 cells/mm3 increase) 
1.10 1.04-1.16 <0.001 1.11 1.05-1.17 0.0003 
Age  (ref:> 7 years)       
≤ 7 years 1.03 0.54-2.00 0.916 1.60 0.68-3.76 0.283 
Adherence over time (ref=<95%)       
≥95% 1.99 0.99-3.99 0.052 3.56 1.45-8.77 0.006 
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3.2 Discussion of the manuscript  
 
The aim of this manuscript was to assess ART adherence in a rural paediatric cohort and is 
responsive to all three primary objectives listed in the introduction chapter. The hypothesis 
driving this analyses was based on monthly adherence assessment by pill count, when defined 
as >95%, being a reliable predictor of virological outcomes. Descriptive statistics were used to 
describe the baseline characteristics. Sensitivity and specificity was calculated for high/low 
adherence to evaluate how well they predicted viral suppression. McNemar’s chi-square test for 
dependent samples was used to determine whether there is a difference in the proportion of 
high/low adherers when measured using pill count or viral load. Generalised estimating 
equations were was used to identify predictors associated with undetectable viral (<400 
copies/ml) load over time.  The variables included in the model were: adherence > 95%, age, 
gender, who stage, whether parent(s) is/are alive and primary caregiver. Statistical analysis was 
performed using SAS Version 3.2 (SAS Institute, Cary, North Carolina). 
Overall median adherence for all 78 children remained above 85% over the two year follow-up 
period. The proportion of children with an undetectable viral load (< 400 copies/ml) were 
84.0% (n=63) at month six, 86.6% (n=58) at month 12, and 84.5% (n=49) at month 24. 
Disappointingly, no agreement was found between adherence by pill count >95% and viral load 
results. Pill count showed poor sensitivity to predict non-adherence in comparison to viral load. 
Multivariate analysis showed an association between children with an overall adherence by pill 
count >95% and having an undetectable viral load. Multivariate analysis also predicted that 
children with a baseline WHO stage 3 or 4, if the primary caregiver was a family member 
instead of the biological parents and if the primary caregiver was the recipient of any financial 
grant were possible predictors for a child to have an undetectable viral load < 400 copies/ml. 
The most common reason reported for children to be non-adherent to ART was the caregiver / 
patient forgot to take treatment (31%).  
This study demonstrated sustained high adherence to treatment over a two year period, with pill 
count being a good tool to measure adherence and viral load assessment remaining the gold 
standard for assessing treatment success. More research is needed on the influence, importance 
and role that the primary caregiver has on ART adherence in children. It should also be 
considered that pill count can be a useful adherence monitoring tool.  
 
Supplementary figures not presented in the manuscript can be found in Appendix O.  
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CHAPTER 4: OVERALL DISCUSSION 
 
4.1 Discussion of major findings   
 
To achieve maximum benefit and optimum clinical outcomes from ARVs, suppressing viral 
load, improving quality of life, decreasing mortality and morbidity, good adherence to ART is 
of utmost importance. The aim of this retrospective study was to assess monthly adherence 
outcomes for HIV infected children on ART in a rural South African community, together with 
self-reported reasons for non-adherence by the children and primary caregivers. Pill count was 
compared with viral load to determine whether pill count can be used as a reliable predictor of 
virologic failure. If the pill count is found to be a possible predictor of virologic outcomes, 
adherence challenges will hopefully be recognized by the pharmacist long before the child 
experiences treatment or virologic failure. This would potentially improve the quality of care 
and improve clinical outcomes for children on ART in the long run. 
This study contributed further evidence to findings from previous studies where pharmacy 
adherence measures, such as pill count, were proven to be useful to monitor adherence and 
predicted virologic outcomes for children on ART. We demonstrated that good adherence was 
attainable and virologic outcomes were sustainable over a 24 month period for children in our 
rural community. Although pill count should be used as an informative monitoring tool in 
clinical care, we advise that viral load should remain the gold standard to monitor treatment 
outcomes. 
Each objective of this study was met as follows: 
4.1.1 Objective 1: To evaluate the adherence in HIV-infected children in a rural community 
in KwaZulu-Natal, South Africa on antiretroviral treatment by comparing monthly pill count 
data with viral load 
This study found that overall median adherence by pill count for the 78 children throughout the 
two year follow up period was good and remained above 85% throughout. There was no 
significant difference in overall median adherence by pill count over time for children 
considering baseline demographics such as gender, which parent was alive, WHO staging and 
the primary caregiver status (Appendix O – additional data).  
Similar to our findings, other rural cohorts in Africa found a positive association between 
medications returned /pill count and viral load (8, 23). However, the association between 
adherence and virologic outcomes in other studies (19, 22, 36) have given inconsistent results. 
Previous literature suggested that adherence of > 95% should be maintained for a patient to 
achieve virologic suppression and good clinical outcomes (26), and this percentage is often used 
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in clinical practice when assessing a patient’s adherence. Similar results were found with a high 
proportion of children achieving an undetectable viral load in our study and other studies 
conducted in South Africa (8, 9) and Rwanda (44). Of the children in a prospective cohort study 
in Cape Town, 78% achieved undetectable viral load (8) and in Kigali, Rwanda, an undetectable 
viral load was attained for 82.8% children (44). In the Cape Town cohort the percentage of 
children achieving medication return adherence > 90% was 79%, and approximately 58% of the 
children achieved an adherence above >95% (8).  
Even though an association was found between adherence by pill count >95% and virologic 
outcomes, the proportion of children having an undetectable viral load with adherence by pill 
count >95% at the three time points in our study showed low agreement. Pill count had a low 
sensitivity to predict viral load outcomes. Sensitivity, specificity and accuracy of an adherence 
measure can be influenced by the cut-off points used to define the level of adherence (41). It is 
evident that the standard definition used in adults, where it is advised to have an adherence 
>95% to achieve virologic suppression, may not be similar for children. With pill count (cut-off 
95%) showing poor sensitivity when used cross-sectionally to predict non-adherence in 
comparison to viral load in our study, we suggest that the gold standard for assessment of 
adherence to treatment should remain viral load assessment.  
Ethiopian children with baseline WHO stage 3 and 4 were more adherent to their treatment (28) 
as were children with WHO stage 2 or 3 in Cape Town (8). These results are consistent with our 
study which concluded this is an important predictor for a child to have an undetectable viral 
load. WHO stages 3 and 4 are both influenced by malnutrition which can lead to poor adherence 
in children (43). It is possible that children with more severe disease along with their primary 
caregivers may be more motivated to be adherent to treatment in the setting in which we work.  
Pharmacy adherence measures such as returned pill count can play an important role in 
monitoring adherence (37), especially to confirm whether the patient understands their ARV 
regimen dosing and if good clinical outcomes can be expected in between annual safety bloods 
being done. However studies suggested that multiple measures, and not pill count alone, should 
be used to predict adherence to maximize the reliability and validity of data collected (13, 14). 
The use of the monthly pill count in our setting assisted us in identifying adherence related 
barriers or challenges in between viral load monitoring bloods enabling these barriers to be 
addressed by referral for additional care to the counsellors and clinicians. 
Other possibilities for poor adherence by pill count can be attributable to errors such as 
measuring and administering liquid formulations. Administering the correct quantity of liquids 
is challenging; caregivers may not always have a syringe available for administration and 
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spillage can happen during administration. Pill count also relies on the child returning all unused 
medication at the next scheduled visit which were often not done as children came to the clinic 
after school or the primary caregiver came alone to collect treatment when the child was away 
from home. Pill dumping in toilets or outside bins at the clinic has occurred at our setting where 
children deliberately threw away extra pills before visiting the pharmacy to hide the possibility 
of non-adherence. This may have over-estimated adherence in our study. Children and their 
primary caregivers are prone to act in socially desirable ways, as they know that any 
discrepancies with medication returned will be questioned. The children / primary caregiver 
should have an understanding that the measures used by pharmacy to monitor adherence are 
necessary to ultimately improve treatment outcomes.  
 
4.1.2 Objective 2: To identify reasons for non-adherence as reported by the patients or 
caregiver themselves  
Reasons reported for non-adherence were collected by self-report thus, the results may have 
been impacted by social desirability bias. The reason most frequently reported for non-
adherence in our study was forgetfulness of the primary caregiver and / or the paediatric 
(30.97%). This is similar to other studies where forgetfulness by the caregiver was also 
distinctly recognised as a frequently reported reason for non-adherence (12, 16, 28, 32). It is 
pertinent that due consideration be given to the role of the primary caregiver in adherence 
outcomes for children on ART.  
Child felt too ill to take medication, a change in daily routine and child ran out of medication 
were some other reasons reported for non-adherence in our study and was similar to previous 
findings (58, 62). All caregivers and children in our study were continuously counselled on 
what possible side-effects to expect and were advised to return to the clinic if any of these 
occurred for further management. This may be the reason for the low frequency of side effects 
of antiretroviral medication (0.19%) reported as a reason for non-adherence in this study as 
compared to 16.3% and 4.3% in Ethiopian studies (58, 62) and side-effects of antiretroviral 
medication was found to be a predictor of adherence in Northern Tanzania (60). Educating 
caregivers and children on side-effects, contra-indications and how their ARVs work to fight 
HIV should be part of adherence counselling performed by pharmacy.  
Information that was not collected in our study was the impact that disclosure could have on 
adherence. A randomized, partially blinded trial which collected adherence data through self-
reported questionnaires by caregivers concluded that the fear of disclosure was a significant 
reason for non-adherence (5). Caregivers in South India, where none of the children had been 
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disclosed to and none knew their HIV status, reported that they were concerned about disclosure 
and the impact it will have once the children are older (11). For HIV infected children, 
caregivers often choose for their children not to be disclosed to, due to fear for stigmatization 
(65). It is possible that disclosure of the child’s HIV status might reduce stress and improve 
adherence support, but one has to consider what impact this will have on potential for 
discrimination and stigma for children. To resolve the challenges introduced by stigma and 
disclosure, involvement from a multidisciplinary team and support from the community is 
needed. 
 
4.1.3 Objective 3: To analyse treatment regimens and any single drug or complete switches to 
determine if virological failure and / or medication side-effects can be linked to non-
adherence 
Regimen and single / complete drug changes can be related to virologic failure, medication side-
effects, clinical toxicity or non-adherence. In our study only four children were changed to 
second line treatment related to treatment failure at their month 12 visit and one child at month 
24 visit. The overall median adherence for all five children at months six, 12 and 24 was 95.1%, 
80.3% and 100% respectively. After regimen changes occurred, all five children achieved viral 
suppression. For one child a detectable viral load was noted 11 months after regimen change 
due to non-adherence. Little information is available on drug switches related to treatment / 
virologic failure in paediatric literature. The availability of child friendly ARVs is limited.  
In our study, treatment failure and poor tolerance to ART resulting in drug switches were rare. 
Three children had a single-drug switch on first line treatment due to laboratory / clinical 
toxicity (two were for hyperlactatemia and one for suspected abacavir allergy). In a Rwandan 
cohort, 8.3% of the children had to change regimens due to toxicity compared to only 3.8% in 
our study (44). The low percentage of changes due to clinical toxicities can be related to 
toxicities being difficult to diagnose by nurses, although all the nurses at our clinic are highly 
trained and all suspected clinical toxicities are referred to the clinician for follow-up. 
Continuous education and training of health care professionals is vital and key to provide 
quality of care.  
A major difference between our study and that of others is the association found between age 
and adherence. Age of the child was a predictor for adherence in the cross-sectional study 
conducted in Lome, Togo (13), a prospective Zambian study (47) and a cross-sectional South 
Nigerian Study (12). In the United States, a randomized, partially blinded trial concluded that 
children above the age of 10 years were likely to be more adherent to their treatment (5), 
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however this US study did not collect detailed data on the primary caregivers and the sample 
size of children older than 10 years was small. Similarly, in Jamaica, older children receiving 
family care were more likely to be adherent (16). Younger children are often more reliant on the 
primary caregiver to take responsibility for ART adherence as compared to older children who 
tend to take over this responsibility but then have to possibly deal with stigma and judgemental 
issues around the mode of acquiring their disease. Children mature at different ages, thus 
accurate assessment of the child’s readiness and capacity to take responsibility for ART should 
be considered, but the need for children to take the responsibility from an early age might 
improve treatment outcomes.  
The inconsistent results of the influence of the parent as the primary caregiver on adherence and 
virologic outcomes should be investigated (8, 18, 23). Responsibility shifting of ART is 
possible when the biological parents are not always able to supervise medication administration 
due to daily responsibilities. To maintain continuity of care, the importance of a reliable 
secondary caregiver and handover of responsibilities when primary caregivers are not around 
were highlighted as a challenge in our cohort and should be investigated. This also highlights 
the importance of counsellors in understanding the relationship between the child and primary 
caregiver. Counsellors should consider tailoring counselling messages to improve the 
relationship between the child and primary caregiver and possibly considering disclosure of the 
child’s HIV status from an early age to empower them to take full responsibility for their own 
health and to understand the implications of poor adherence. 
Other primary caregiver related factors that have been associated with poor adherence are 
financial difficulties, economic household problems, limited disposable income and the socio-
economic status of the caregiver (8, 9, 54, 56). Similar barriers, higher income levels and 
monthly household income, have also been associated with virologic outcomes in other studies 
(47, 50, 60). In our study children with caregivers who were the recipients of any financial grant 
were more likely to have an undetectable viral load. Financial impediments often hinder the 
children and caregivers to adhere to clinic appointments which ultimately has a negative impact 
on treatment adherence. In our study children and caregivers often had to make use of public 
transport to come to our clinic due to longer travelling distances. If they did not have the money 
for transport, they missed their clinic appointment dates and only came back once they had the 
available funds.  
These findings highlight the challenge for healthcare staff to better understand adherence in 
children, the effect the primary caregiver has on adherence and the barriers that need to be 
addressed to improve medication adherence in children on ART. More research should be 
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conducted with regards to the primary caregiver and the support they need to ensure good 
adherence and clinical outcomes for their children. Continuous training on paediatric ART 
adherence should be included at health facilities to ensure that all healthcare staff understand the 
regimens, dosing strategies and possible barriers faced by caregivers.  
To improve adherence, memory aids in our study consisted of weekly pillboxes and cell phone 
clock reminders which were set to fit the children’s daily routines. We assisted our caregivers 
and children in packing these weekly pill boxes during their visit at the pharmacy, labelling the 
daily or twice daily pill boxes with sun / moon pictograms, together with setting a cell phone 
alarm reminder. At the next contact visit they were to return the pill box together with any 
remaining tablets. However not all children liked the pill boxes as they were concerned it would 
raise unwanted questions from friends and other family members. In an Ethiopian study, the 
majority of caregivers (67.1%) reported that they were using their watches as a reminder (28). 
In a rural setting, the availability of cell phones is limited and when the primary caregiver is not 
always available or is often away from home when the child has to take the medication, doses 
could be missed. The child might then be asleep when the caregiver returns home. After 
identification of this barrier we advised the children to find an alternative reminder, this 
included coinciding ART dosing with a television program or any activity which was repeated 
daily. This encouraged them to be more responsible for taking their own medication. 
 
4.2 Study limitations      
   
This study has several limitations. HIV disclosure and its correlation with adherence outcomes 
was not measured in our study. Not all medication was returned at each of the monthly visits as 
sometimes relatives were sent to collect medication which may affect accuracy of the adherence 
assessment. Self-reported reasons for non-adherence are always subject to recall bias and a 
desire to please the provider. In addition, all children and caregivers knew what to expect at the 
visit which included the pill count and questioning about any discrepancies. Information on who 
reported reasons for non-adherence was not collected.  This should be taken into inconsideration 
due to the difference in agreement of self-reported reasons by caregivers and children reported 





4.3 Recommendations for clinical practice   
 
The pill count contains valuable information which could easily be incorporated into clinical 
care as a monitoring tool. Pill count should be completed at the beginning of the visit before the 
child is seen by the clinician, nurse or counsellor. This will not only minimize the deliberate 
possibly ditching of any extra pills before coming to the pharmacy, but will also ensure that 
early detection of adherence challenges are referred for timeous action. Educating and 
empowering children to take the responsibility for their own health from an early age including 
age-appropriate disclosure of their HIV status should be considered and discussed with the 
primary caregiver before commencement of ART. The mode of acquiring their disease should 
be taken into account when disclosure is being discussed. 
In a multidisciplinary healthcare team, the pharmacist, may play the role of a child’s primary 
adherence supporter as many of the children have often lost family members due to HIV related 
illnesses. These children are also in desperate need of social support, peer support groups, 
disclosure guidance and for medical staff to be more sensitive and knowledgeable about each 
individual’s history and treatment management. 
The role of the pharmacist in clinical practice should be centred and focussed on improving 
patient medication adherence. Pharmacists have the necessary medication expertise to improve 
and minimize non-adherence through patient-contact. Patient specific barriers and challenges 
should be identified and suitable interventions to overcome these should be discussed in 
consultation with the patient.  
A healthcare team effort is needed to address non-adherence and find future interventions that 
are children specific and sustainable. 
 
4.4 Recommendations for future research  
 
Globally, a standard definition for paediatric adherence and a reliable and valid measure of 
adherence is required for any future studies on paediatric adherence on ART in rural settings.  
Previous studies have also highlighted methodological challenges when comparing data. The 
fact that the methods used to measure medication adherence differ across studies (45), recall and 
social desirability caused by self-report (32) are difficult to account for and the inconsistent 
results for adherence being a predictor of virologic response (23) are some aspects that need 
standardisation in paediatric ART care. Furthermore, the appropriate cut-off point to define 
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medication adherence in children should be investigated and standardization of measures of 
monitoring adherence should be studied and compiled (46). 
Little has been done to investigate sustainable interventions to improve medication adherence 
for children on ART. Adherence interventions and research need to include the psychosocial 
influence of HIV (43). These interventions should be cognisant of all the possible factors 
influencing adherence including medication related factors, healthcare related factors, caregiver 
related factors and child related factors. Considering these factors, future research should focus 
more on the effect that early disclosure in children has on their adherence. Both the primary 
caregiver and paediatrics’ ideas, problems and understanding about antiretroviral treatment and 
adherence should be studied and investigated (17, 35, 44). Suggestions were also made to 
educate the caregiver and the medical staff about good adherence practices, to make sure 
relevant people fully understand medication dosing and administration (55). Continuous 
education is needed to make HIV infected children more responsible to take their own 
medication and to be less reliant on the primary caregiver. To include the entire family in the 
treatment process compared to only having one primary caregiver, might add more reliability to 
the support and treatment outcomes of the paediatric (9).  
Even though pill count is readily available in limited resource settings to use as an adherence 
measure, barriers influencing self-reported reasons for non-adherence / missing doses by 
primary caregivers or children need to be investigated.  
 
4.5 Concluding statements  
 
Overall adherence by pill count for HIV infected children on ART was good with patients 
visiting the clinic monthly for treatment collection and clinical follow-up. Increased monthly 
contact with the children and their caregivers assisted the pharmacist to build a relationship that 
was more than just a professional relationship. Honesty and trust was emphasized throughout 
the treatment program. Pharmacists worked in conjunction with other health care staff to ensure 
quality of care for these children. During the five year follow up period our pharmacy 
maintained stock levels of three months of medication per patient per ARV and therefore did 
not experience any medication stock-outs. Treating, managing and following these children 
during the CAPRISA 052 AIDS Treatment program was a team approach which made it 
possible to be a great success.  
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In conclusion, this treatment program proved that high adherence in a rural paediatric cohort in 
South Africa is possible. Secondly, although adherence of >95% by pill count was found to be 
associated with viral load suppression and is a good, relatively easy method to monitor 
adherence at each contact visit, assessment of viral load is still the best measure of treatment 
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